Clinical Trial Update: A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial evaluates an oral norovirus G1.1/G2.4 vaccine in healthy adults aged 18-80, sponsored by Vaxart.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Norovirus Infections

Drugs mentioned

• Norovirus G1.1/G2.4 oral vaccine

Snippet

Sponsor: Vaxart | Conditions: Norovirus Infections | Phase 1 | Status: ACTIVE_NOT_RECRUITING